跳至主要内容
临床试验/EUCTR2017-004540-37-IT
EUCTR2017-004540-37-IT进行中(未招募)1 期

The effects of sequential Mitomycin and Bacillus Calmette-Guérin treatment versus Bacillus Calmette-Guérin monotherapy in patients with High risk Non-Muscle Invasive Bladder Cancer - MITOBCG

AZIENDA OSPEDALIERA SANT'ANDREA0 个研究点目标入组 140 人开始时间: 2021年9月6日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
140

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • -patients with High grade Non-Muscle Invasive Bladder Cancer
  • - high progression risk ((EORTC risk score >6)
  • - Age > 40 years old and < 75 years old
  • -signed written informed consent form
  • - capacity for discernment
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 66
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 66

排除标准

  • oLow Risk Non-Muscle Invasive Bladder Cancer
  • oMuscle Invasive Bladder Cancer
  • oConcomitant Urothelial Bladder Cancer in the Upper-Urinary Tract
  • oPrevious bladder or prostate surgery
  • oProstate or bladder radiotherapy
  • oUrinary tract infection
  • oChronic urinary retention or indwelling catheters
  • oNeurological patients
  • oPrevious BCG infections
  • oPrevious or current chemotherapy for other kind of cancers
  • oPatients older than 75
  • oWHO performance status 3-4
  • oResidual tumour on re-TURB

研究者

相似试验

Combination therapy in bladder cancer | 临床试验